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ABSTRACT The solid-state structure and behavior of tartrate (MT-o) and succinate (MS-m) 
metoprolol salts have been studied with a combined experimental (XRD by both single crystal 
and microcrystalline powder and DSC) and modeling approach (MD and MO calculations). In 
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spite of their close similarity at the molecular level in the corresponding crystal lattices, 
calorimetric data suggest for MS-m a slight greater cohesive energy. In addition and more 
importantly, they show significantly different “macroscopic” behaviors: MS-m undergoes a 
reversible anisotropic lattice expansion/contraction upon temperature change and once melted 
quickly re-crystallizes to the starting crystal phase. On the other hand, MT-o expands/contracts 
isotropically, and upon cooling from the melt gives an amorphous solid, which, at ambient 
conditions, takes six days to completely revert to the starting crystal form. Both findings are 
relevant in the field of the pharmaceutical drug development, i.e. when the phase purity of these 




It is well known that several physical and chemical properties such as solubility, dissolution rate, 
melting point, density and chemical reactivity of an active pharmaceutical ingredient (API) can 
affect its processability and quality.1 Given that most of the above-mentioned properties depends 
on the crystalline structure of the API,2,3 the study of its solid state forms and of their behavior 
under certain storage conditions, is essential when dealing with pharmaceutical compounds.  
In addition, although the most stable form of an API is usually employed in formulations, 
sometimes it may be convenient to use a metastable form in order to enhance its bioavailability. 
As a consequence, the knowledge of the relative polymorphic stability under defined conditions 
of temperature and pressure assumes a crucial role.  
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Bearing in mind what is stated above and considering that solid-solid transformations, e.g. 
phase transformations, solvation/desolvation processes as well as chemical reactions, can occur 
in response to variations  in environment (temperature, ambient/vacuum pressure, humidity), 
manufacturing, storage, or simply over time, monitoring the API behavior under different 
experimental conditions appears to be essential.4 
In this context, spectroscopy, X-ray diffraction, both from single-crystal (SCXRD) and 
microcrystalline powder (XRPD), solid state NMR, thermal analysis (in particular differential 
scanning calorimetry, DSC), microscopy and molecular modeling are commonly used as 
interdisciplinary tools for characterizing pharmaceuticals,  including APIs and formulations.5,6,7 
Indeed, these techniques provide insights on the molecular and crystal structure of the solid 
forms, their phase distribution, their transformations, the heats and temperatures related to phase 
transitions, solvation/desolvation processes and decomposition.8,9 Moreover, computational 
methods can provide a plethora of complementary information (molecule's conformational space, 
molecule’s potential energy surface, role of intra- and/or inter-molecular interactions in driving 
the 3D arrangement of molecules having a large number of degrees of freedom, etc.) useful to 
rationalize the solid state results.10   
Herein we report a solid state study on the succinate and tartrate metoprolol salts (MS and 
MT, hereafter). Metoprolol, (±)-1-isopropylamino-3-[4-(2-methoxy-ethyl)-phenoxy]-propan-2-ol 
(Scheme 1), belongs to the class of β1 selective β-adrenoreceptor blocking drugs,
11 and is widely 
used to treat heart failure and cardiovascular diseases, such as hypertension, angina, acute 
myocardial infarction, ventricular tachycardia, just to name a few.12,13 Due to the fact that it has a 
quite low melting point (~323 K, as determined by differential scanning calorimetry, DSC)14 and 
that drugs that melt below 373 K are difficult to manufacture, metoprolol is commonly 
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administered as succinate (MS, melting point around 409 K) or tartrate (MT, melting point 
around 393 K) salts. While the tartrate salt is used in immediate-release formulations, the 
succinate one is used in extended-release dosage forms:15 both formulations contain the 
metoprolol cation and the dicarboxylate anion in a 2:1 ratio. In both cases the metoprolol 
molecule is present as a racemic mixture and, in MT, the dextrorotatory enantiomer of the 
tartrate anion is used. Incidentally, the cardiac β-blocking activity of metoprolol, as most of the 
β-blockers, resides in the S-isomer.16  
MS and MT have been the subject of numerous studies mainly related to pharmaceutical 
technology,17,18,19 clinical pharmacology,20,21 pharmacokinetics,22,15 spectral,23 thermal24 and 
structural characterization.14,25,26 In particular Ionescu and coworkers14 have investigated MT by 
single crystal and powder X-ray diffraction, hot stage microscopy and DSC. As for the solid state 
structure, they found that, irrespective of the different crystallization procedures employed, MT 
always crystallizes in the space group P21 (hereafter this crystalline form will be referred to as 
MT-m), whose asymmetric unit comprises a pair of 2:1 metoprolol cations and dextro-tartaric 
acid anion. Finally, the XRPD pattern computed from the single crystal data (collected at 173 K) 
is in keeping with the experimental one and agrees well with that already reported by Luch.25 In 
other words, results reported by Ionescu14 and Luch25 refer to the same crystalline form of the 
salt, namely MT-m. As for the succinate salt, the solid state structure from single crystal X-ray 
diffraction at 200 K (monoclinic crystal system, MS-m, hereafter)  has been reported by Di 
Vaira et al.26 
The goal of the present work is to better characterize and understand the solid state behavior of 
such metoprolol salts under different experimental conditions [temperature, atmosphere 
(vacuum, air, N2), time of storage], by using a combined experimental approach (XRD by both 
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single crystal and microcrystalline powder and DSC). In particular attention has been paid to 
possible XRPD pattern changes by applying heating/cooling cycles to the MS and MT samples. 
Results from thermal and XRD analyses are compared and discussed. To complete the picture, 
the conformational space of a metoprolol-like cation has been assessed by DFT calculations and 




Materials and methods. Both Metoprolol succinate (MS) and tartrate (MT) salts  were 
purchased from Sigma Aldrich (grade: primary reference standard, CAS numbers 98418-47-4 
and 56392-17-7 for MS and MT, respectively) and used as received. Reagent grade solvents 
were used. 
Single crystal X-ray diffraction (SCXRD). Numerous attempts were made to obtain single 
crystals of MT suitable for SCXRD analysis. The best crystals, even if not excellent, were 
obtained by slow evaporation from a 1:2 methanol:n-butanol solution. Several crystals were then 
tested by X-ray diffraction and the best one was utilized for the data collection. Single crystal 
diffraction measurements were carried out at 100 K, with an Oxford Diffraction Excalibur 
diffractometer using a Cu-Kα radiation (λ = 1.54184 Å). Data collection was performed with the 
program CrysAlis CCD.27 Data reduction was carried out with the program CrysAlis RED 
(CrysAlis RED, 2006).28 Absorption correction was performed with the program ABSPACK in 
CrysAlis RED. The metoprolol tartrate salt crystallizes in the orthorhombic crystal system, space 
group P21221 (this crystalline form hereafter will be referred to as MT-o). 
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The structure was solved by using the SIR-97 package29 and subsequently refined on the F2 
values by the full-matrix least-squares program SHELXL-97.30 
Geometrical calculations were performed by PARST97,31 and molecular plots were produced 
by the programs ORTEP-3,32 Mercury (v3.5)33 and Discovery Studio Visualizer (v2.5.5.9350).34 
All the hydrogen atoms were included in geometrically generated positions and refined in 
agreement to the atoms to whom they are bonded, although the two ammonium and the hydroxyl 
H atoms of the two metoprolol cations could be clearly identified in difference Fourier maps. All 
the non-hydrogen atoms were refined anisotropically.  
The correct absolute structure was chosen on the basis of the chirality of the naturally  
occurring form of tartaric acid [i.e. L-(+)]. In table 1 crystal data and refinement parameters of 
MT-o  are reported. 
 
X-ray microcrystalline powder diffraction (XRPD). XRPD measures were carried out at 
room temperature in air by using a Bruker New D8 Da Vinci diffractometer (Cu-Kα radiation, 40 
kV x 40 mA), equipped with a Bruker LYNXEYE-XE detector, scanning range 2θ = 3-50°, 
0.02° increments of 2θ and a counting time of 0.8 s/step.  
In order to determine the crystal parameters of MT at room temperature, a scan was performed 
in capillary, followed by the Pawley fit with the software TOPAS.35 A shifted Chebyshev with 8 
coefficients and a pseudo-Voigt function were used to fit background and peak shape, 
respectively. Refinement converged with Rwp = 7.23 but the diffractogram shows the presence of 
two spurious peaks (2 = 17.5, 19.6°) not assigned to any phase (see figure S1). 
Temperature-resolved experiments (performed in triplicates) were carried out: 1) in vacuum in 
the range 173-303 K and in air (range 303-413 K) by using a Bruker D8-Advance (Cu-Kα 
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radiation, 40 kV x 40 mA) equipped with a multi-channels energy dispersion detector (SOLX) 
and a MRI (Material Research Instruments) heating stage for temperature-dependent 
measurements. Scanning range 2θ = 3–50°, 0.02° increments of 2θ and with a 1 s/step counting 
time; 2) under nitrogen in the range 303-420-303 K with an Anton Paar HTK 1200N hot 
chamber mounted on a Panalytical XPERT PRO diffractometer (Cu-Kα radiation, 40 kV x 40 
mA), equipped with the PIX-CEL solid state fast detector. Scanning range 2θ = 3–50° with a 1 
s/step counting time and 0.03° increments of 2θ.  
In all cases the temperature variation rate was 10 K/min, after the target temperature was 
reached the sample was kept 10 minutes at that temperature before proceeding with data 
collection.  
Finally, cell parameters at different temperatures were obtained with the same procedure 
described above. 
 
Differential Scanning Calorimetry (DSC). Differential scanning calorimetry (DSC) 
experiments were carried out using a Mettler Toledo DSC1 Excellence. Measures were run in 
sealed aluminum pans (mass samples range from 1 to 6 mg). Temperature and enthalpy 
calibration were done using indium as a standard. Melting point (Tm) and heat of fusion (ΔH) of 
metoprolol tartrate were determined by measurements in the 300-410-300 K range, while for 
metoprolol succinate experiments were performed in the 300-430-300 K range. In all cases a 
linear heating rate of 5 K/min was used. Experiments were carried out under nitrogen (the flow 
rate of dry nitrogen gas was 70 mL/min) as well as in air. DSC peaks were analyzed using the 
STARe software.36 The melting data reported were the average of two measurements, standard 
errors were ±0.1 K for temperature and ±0.3 kJ/mol for enthalpy. 
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Molecular Modeling. Geometry optimizations (MM) and molecular dynamics (MD) 
simulations were performed on BS_aT, BS_TG- and BS_TG+ as representatives of the three 
conformational families identified by the solid state structure survey (details in the Result and 
discussion section). All calculations were made by using the CHARMm Force Field.37 MM 
calculations were performed on each species by using the Smart Minimizer energy minimization 
procedure implemented in Accelrys Discovery Studio 2.134 and before starting the MD 
simulations, the geometry of each compound was further optimized using the steepest descent 
and conjugate gradient algorithms. MD simulations were carried out at 100 and 300 K, both in 
vacuum as well as in an implicit water model; water calculations were performed mimicking the 
solvent by using a distance-dependent dielectric constant of 80. In the molecular dynamics 
simulations, the time step was 1 fs for all runs, equilibration time = 100 ps and production time = 
1000 ps, snapshot conformations were sampled every 10 ps. The programs used for the MD and 
the energy minimization were the Standard Dynamics Cascade and Minimization protocols, 
trajectories were analyzed by the Analyze Trajectory protocol, all implemented in Discovery 
Studio 2.1.  
GAUSSIAN09 (Rev. C01)38 was used for molecular orbital (MO) calculations using the following 
functionals: B3LYP39,40 and B97D.41 The basis set was 6-31+G(d,p).42 The Berny algorithm was 
used.43  The reliability of the stationary points was assessed by the evaluation of the vibrational 
frequencies. Geometry optimizations were performed on the three conformational isomers 
BS_aT, BS_TG-  and BS_TG+.  
 
RESULTS AND DISCUSSION 
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Single crystal X-ray diffraction and modeling studies. The metoprolol tartrate salt 
crystallizes in the orthorhombic crystal system, space group P21221 (MT-o). In the asymmetric 
unit each of the enantiomers of the metoprolol and two halves of the tartrate anion are present.44 
In figure 1 an ORTEP-3 representation of the two cations is reported. The two independent 
cations of metoprolol in the asymmetric unit are related by a pseudo-mirror plane, as depicted in 
figure 2, where the superimposition of the R enantiomer and of the mirror plane-image of the S 
one is reported. Due to the presence of this pseudo-mirror (that has been observed in MT-m  
too45), and considering that the S enantiomer has a cardiac β-blocking activity significantly 
higher than the R one,46 in the following attention will be focused on the S-isomer. 
A survey of the Cambridge Structural Database (CSD, v. 5.36, February 2015)47 gives eleven 
compounds featuring the molecular fragment sketched in scheme 2a.48 As for the charged 
species, on the basis of the dihedral angles characterizing the conformation of the chain bearing 
the isopropyl group (i.e.: C6-C1-O1-C7, C1-O1-C7-C8, O1-C7-C8-C9, C7-C8-C9-N1, see figure 
1),49  two main conformational families can be recognized: an elongated conformation (all-trans, 
aT hereafter), observed in the structure with Refcode JIRWIR50 and in MT-o  and a more 
compact disposition (gauche about the C7-C8 bond, hence ttgt family) as in MS-m26 (vide infra), 
in CIMJUD,51 in QAJYIL and in DETHIU.52,53 The second family can be further divided into 
two groups depending on the sign of the gauche dihedral angle about the C7-C8 bond: negative 
in MS-m and CIMJUD (ttg-t, TG-  hereafter) and positive in DETHIU and QAJYIL (ttg+t, TG+ 
hereafter). These folded conformations feature a weak54 CH2
…O intra-molecular H-bond (C9-
H…O1 distances and angles range from 2.3 to 2.5 Å and from 98 to 114°, respectively) forming a 
five-membered ring that could contribute to stabilize the TG families.  
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In the neutral species (iPr-amine tail) four major44 kinds of conformational isomers can be 
recognized. 
This is well illustrated in figures 3 and 4, which show the superimposition of the X-ray 
structures of the cationic and neutral species. Finally, when neutral and charged species are 
considered all together they grouped in five distinct families: the most representative is the all 
trans one that encompasses the conformation found in MT-o (figure 5). 
Moreover, a special comment deserves the molecular structure of the metoprolol in the strictly 
related MT-m14 and MS-m26 salts. As for MT-m, the metoprolol cation shows a conformation 
very similar to that found in MT-o (see table 2 for a comparison of the torsion angles defining 
the 3D arrangement of the phenyl side arms in the S enantiomers).45 On the contrary, the 
metoprolol cation overall shape in MS-m differs from that observed in MT-o (see figure 6 and 
table 2), due to the torsions about the C7-C8 bond of the iPr chain (g- or –synclinal in MS-m and 
t or antiperiplanar in MT-o) and the C13-C4 bond of the 2-methoxyethyl chain (g+ or +synclinal 
in MS-m and -anticlinal in MT-o).55 
In summary, the solid state data show at least three different conformations for the positively 
charged tail (figure 3), while for the methoxy chain two different 3D-arrangements were found 
(figure 6). 
Given that metoprolol shares the 2-hydroxy-3-isopropylaminopropoxy group with other β-
adrenoreceptor blocking agents, such as, for instance, atenolol, practolol, pindolol and 
bisoprolol, it might be of some interest to get an idea of the conformational behavior of such a 
tail by investigating the basic structure (BS, see scheme 2b) common to all the above mentioned 
β-adrenoreceptor antagonists by Molecular Dynamics (MD) and MO (DFT) methods.  
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The BS_aT, BS_TG-, and BS_TG+ conformers, representative of the three conformational 
families (all trans, ttg-t and ttg+t, respectively) identified by the solid state structure survey above 
discussed, were then used as starting points for MD simulations performed at 100 and 300 K, 
both in vacuum as well as in an implicit water model. Notwithstanding the starting isomer 
(BS_aT, BS_TG-, and BS_TG+), the large majority of the conformations collected at 300 K in 
vacuum shows a “doubly-folded” arrangement (which is completely different from those 
observed in the solid state, figures S2-S4) about the C7-C8 and C8-C9 bonds stabilized by a 
strong intramolecular H-bond50 between the ammonium grouping and the oxygen atom O1 
(mean NH2
+…O distance 2.0 Å). The different conformational preference in vacuum with respect 
to the solid state is not surprising if considering that the crystal lattice is held together by strong 
intermolecular H-bonds between the ammonium and the hydroxyl groups of the cation and the 
counterions (vide infra), which most probably drive the arrangement of the charged side arm. 
The inclusion of a distance dependent dielectric constant makes the intramolecular interactions 
almost completely vanish in MD simulations performed at the same temperature and in most 
cases the charged tail adopts an elongated conformation (figures S5-S6) very similar to that 
found in the crystal structures of MT-o and MT-m, thus supporting the above reasoning. Finally, 
at 100 K the side arm bearing the isopropylammonium group remains trapped within a limited 
region of the conformational space close to the starting rotational isomer, both in vacuum and 
with an implicit water model, thus suggesting that the solid state arrangement of the charged tail 
corresponds to locally stable conformations. This result parallels the outcomes from DFT 
calculations: the optimized structures of the three conformational isomers (BS_aT, BS_TG-, and 
BS_TG+) do not significant differ from the input ones; in addition, they are essentially 
isoenergetic (max ΔG298= 0.8 kcal/mol).  
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Summing up the solid state and modeling data, the chain bearing the isopropyl group is able to 
adapt to the surroundings (in vacuum and in implicit water model as from MD at 300 K and solid 
state data); its conformational space comprises at least three local minima (MD at 100 K and 
DFT data), separated by a quite low energy barrier (MD data at 300 K) given that during a MD 
run the energy barriers that can be easily overcome are on the order of one to two RT.  
As said before, metoprolol and tartrate ions are held together in the crystal packing of MT-o 
thanks to several strong hydrogen bonds54 (see table 3). Due to these interactions, each 
metoprolol cation interacts with two different tartrate anions and, at the same time, each tartrate 
anion interacts with four metoprolol cations (two R and two S, figure 7A). This net of H-bonds 
gives rise to chains, along the c-axis direction, formed by alternating R and S metoprolol cations, 
bridged by the carboxylate oxygen atoms of the tartrate. Moreover, due to the dicarboxylic 
nature of the tartrate, couples of metoprolol chains are held together through the anion (see figure 
7B). As for the hydroxyl groupings of the tartrate anions, they are not involved in any 
intermolecular contact, on the contrary they form intramolecular H-bonds with the carboxylate 
oxygen atoms (details in table S1). Further weak interactions of CH...O type (see table 3) take 
place between the facing methoxyethyl side arms of two adjacent metoprolol chains along the a 
axis (see figure 8). Finally, weak hydrogen bonds involving the iPr chain (see table 3) propagate 
the metoprolol-tartrate interactions along the b axis. 
As for MT-m, Ionescu and coworkers describe "an infinite series of H-bonded rings and 
chains" held together by strong hydrogen bonds involving the carboxylate oxygen atoms of the 
tartrate anion and the ammonium and hydroxyl hydrogen atoms of the metoprolol cation. As 
mentioned above, in the orthorhombic phase described herein (MT-o), the metoprolol cation 
displays a molecular structure almost identical to that of the monoclinic phase (MT-m) reported 
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by Ionescu. As a consequence, we wonder if this could be a case of an isostructural 
polymorphism.56,57 However, from the published data14,48 it is not possible to have a clear picture 
of differences and/or similarities in the supramolecular arrangement of the two solids. 
It is worth noting that in the strictly related MS-m compound,  the pattern of strong hydrogen 
bonds (see table 3 for a direct comparison) which holds together cations and anions is quite 
similar to that found in MT-o: each metoprolol cation forms H-bonds to two anions and each 
succinate accepts H-bonds from four distinct cations thanks to its carboxylate groupings (see 
table 3). Similarly to MT-o, ribbons of H–bonded ions form along the c axis (see figure 9), 
while, at variance, no further significant intermolecular interactions are present, except for two 
C-H...π weak interactions54 that propagate the intermolecular contacts along the b axis (see table 
3). At the same time, such interactions, due to the mutual disposition of the ribbons, interconnect 
them also along the a axis, as evidenced in figure S7 (top). 
In summary MS-m and MT-o show a close similarity at crystal level in terms of strong 
metoprolol-counterion interactions [number, type (H-bond donor and/or acceptor) and geometry 
(H-bond distances and angles)], as well as crystal densities (1.248 vs 1.242 g/cm3calculated from 
SCXRD data collected at 200 K for MS-m26 and at 100 K for MT-o). This observation parallels 
the fact that the hydroxyl groupings of the tartrate anion are not involved in any intermolecular 
contacts. In other words only the carboxylate oxygen atoms of both tartrate and succinate are 
involved in intermolecular H-bonds. 
 
 




The correspondence between the crystal structure of MT, determined by single crystal X-ray 
diffraction (MT-o), and that of the bulk material was checked by indexing a high-resolution 
powder diffraction pattern collected at room temperature in capillary: it indexed to the same 
orthorhombic cell [cell parameters: a = 45.561(1), b = 8.4621(6), c = 9.7381(5) Å, in the P21221 
space group]58 found in the SCXRD experiment performed at 100 K.  
The thermal stability of MT-o was then assessed by combining data from variable temperature 
XRPD and DSC analyses. Two sets of XRPD experiments were performed: in vacuum in the 
range 173 - 303 K; in air and under N2 atmosphere in the range 303-413-303 K. Upon heating, 
the polycrystalline MT-o did not undergo any change until the melting point was reached (see 
figure 10). No recrystallization process was observed during the cooling step from 413 to 303 K 
(see figure 11). DSC measurements performed during a similar heating/cooling cycle (300-410-
300 K) confirmed the previous findings: neither evidences of thermodegradation59 nor 
exothermic peaks in the cooling step (see figures S8 and S9) were observed.  
The amorphous sample was then left in air for four days at room temperature and a XRD 
powder pattern was collected every day for ten days. As evidenced in the diffractogram reported 
in figure 11 (top), it took four days for the recrystallization to begin and six days for the process 
to be completed (patterns collected from the sixth to the fourteenth day are well superimposable 
with each other and match the one collected at room temperature in capillary). The DSC trace of 
the re-crystallized sample shows a single endotherm peak at 394.7 K (extrapolated peak 394.7 K) 
with a melting enthalpy of 155.6 J/g (106.5 kJ/mol,). Both these values nearly exactly match 
those found for a fresh sample of MT exposed for comparative purposes to an identical 
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heating/cooling cycle (300-410-300 K; melting temperature: peak 395.9 K, extrapolated peak 
396.2 K; melting enthalpy: 159.0 J/g, 108.8 kJ/mol.60  
Thus the MT-o sample undergoes a reversible crystalline-to amorphous-to crystalline phase 
transition, where the thermodynamically spontaneous amorphous-to-crystalline step occurs in air 
over time (six days are required to achieve a complete re-crystallization) at room temperature 
(that is above its glass transition temperature,61 as expected). Given that stability over time is one 
of the most critical point for APIs as well as their pharmaceutical formulations, the tendency of 
MT-o to slowly recrystallize from its amorphous form must be taken into account when dealing 
with its pharmaceutical development. In particular this finding appears important when API solid 
forms (amorphous or crystalline) are assessed, discussed and related to different formulations 
and manufacturing processes in view of their pharmaceutical development.62  
As for MS, the correspondence between bulk powder and single crystals was ascertained by 
comparing the experimental XRPD pattern collected at room temperature with the theoretical 
one obtained by using the SCXRD data of MS-m reported by Di Vaira26 (see figure S10 in 
Supplementary Material). 
MS-m does not change phase until melting (melting temperature: peak 410.4 K, extrapolated 
peak 410.8 K; melting enthalpy 175.4 J/g, 114.36 kJ/mol, from DSC measurements). These 
calorimetric data (the higher melting temperature parallels the higher melting enthalpy) suggest 
for MS-m a slight higher cohesive energy with respect to MT-o. After melting, during the 
cooling step, recrystallization to the starting form occurs (see figure S11), as shown by the 
diffraction profiles collected in the range 303-420-303 K (under N2 atmosphere). In other words, 
the MS-m crystal phase appears stable with respect to a heating/melting/cooling sequence.  
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However, a detailed comparison of the diffractograms collected at different temperature (figure 
12) highlighted that, upon heating, while there were no differences in the overall number of the 
peaks, as well as in their relative intensities, several peaks shifted towards lower 2ϑ values, 
unlike others that did not move significantly. The analysis of the collected diffraction patterns 
did not show significant shifts of the (h00), (00l) and (h0l) peaks upon temperature increasing (or 
cooling), on the contrary the (hk0) and (0kl) peaks shifted more evidently (see figure 12). This 
observation led us to postulate the occurrence of a reversible anisotropic lattice 
expansion/contraction along the b axis upon changing the temperature (see figure S11). The 
lattice parameters (table 4) calculated from the diffraction patterns (see Methods and materials 
section) and the linear thermal expansion coefficients (TECs,63,64,65 Table 5) well support this 
hypothesis: the b axis significantly expands with respect to both a (whose expansion is 
negligible) and c (which even slightly contracts) axes.  
The anisotropic expansion observed in MS-m prompted us to reassess its crystal packing in order 
to possibly find a hint for this behavior. The strong H-bonds along the c axis, already discussed, 
can account for the negligible variation of this cell axis upon temperature change. As for the 
other cell directions, weak CH...π interactions connect the metoprolol ribbons along  both the a 
and b axes (see figure S7). However, when considering a possible lattice expansion, we 
reasoning that along the a axis this  should cause a significant change in the orientation of the 
CH bond direction with respect to the mean plane of the aromatic ring (see table 3), while an 
expansion along the b direction seems less affecting such a good directionality (see table 3) and 
could be less dramatic in terms of molecular rearrangement (thus favoring the return to the 
original packing when the temperature decreases). Nevertheless, we are absolutely aware that 
this observation hardly suffices on its own to account for the anisotropic thermal behavior 
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observed, given that the stability of a crystal, and hence its response to an external stimulus 
(temperature, pressure, etc.), depends on a plethora of intermolecular interactions of both 
attractive and repulsive kind.66  
Nonetheless, the anisotropic expansion/contraction observed for MS-m during the 
heating/cooling steps is an important point when the phase purity of the API, as well as its phase 
composition in formulations, is assessed by comparing powder diffraction patterns67. In fact, in 
addition to the expected discrepancies observed in the peak positions when comparing calculated 
XRPD patterns (from SCXRD data usually collected at low temperature) with experimental 
patterns (normally collected at room temperature), unexpected differences, arising from lattice 
expansion/contraction which affect in different extent the lattice parameters, as in MS-m, could 




In this paper we have presented a solid-state characterization of the tartrate and succinate 
metoprolol salts by using a combination of techniques (XRD by both single crystal and 
microcrystalline powder and DSC) in different experimental conditions, while the 
conformational space of the metoprolol-like molecule has been assessed by modeling.  
Crystal structure analyses have revealed that in both salts the metoprolol cation interacts with the 
dicarboxylate anion via strong H-bonds, being the latter comparable in terms of donor-acceptor 
type, strength and number. This observation parallels the fact that the tartrate hydroxyl groupings 
are not involved in intermolecular contacts, that is tartrate and succinate anions are involved in 
the same kind of intermolecular H-bonds. In addition the tartrate and succinate salts have 
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comparable crystal densities, thus suggesting similar packing efficiencies (notwithstanding the 
higher number of weak interactions in MT-o with respect to MS-m). However, calorimetric data 
from DSC measures suggest for MS-m a slight higher cohesive energy with respect to MT-o, 
which cannot be accounted for by considering both strong and weak intermolecular interactions 
alone. On the other hand, the different effect of temperature on the lattice parameters of both 
MS-m (anisotropic lattice expansion/contraction) and MT-o (isotropic) cannot be fully explained 
by the network of intermolecular contacts which stabilize their crystal packing. 
Finally upon cooling, while MS-m quickly re-crystallizes from its molten phase to the starting 
crystal phase, the strictly related MT-o gives an amorphous form and takes six days at ambient 
conditions to achieve complete re-crystallization to the original crystal form. As for this latter 
point, we wonder if, in the amorphous phase, the hydroxyl groups of the tartrate anions could 
play a role in altering the rate of crystallization of this salt with respect to the succinate one, due 
to their ability to form H-bonds. As a consequence the answer to the question “what really makes 
the difference between the crystal samples of MS-m and MT-o and possibly account for their 
“macroscopic different behavior” is still opens and proves once more the absolute necessity to 
perform a full solid state characterization especially when dealing with APIs.  
As for the latter point, the results from the solid state studies as the temperature changes, i.e. the 
reversible crystalline-to amorphous-to crystalline phase transition of MT-o and the anisotropic 
lattice expansion observed for MS-m, are both relevant when dealing with the phase purity of 






Figure 1. ORTEP-3 representation of the two metoprolol cations in MT-o (enantiomer R is 
labelled with a and enantiomer S is labelled with b). 
Figure 2. Superimposition of the R (ball and stick) and of the S (mirror plane-image, stick) of 
the two enantiomers of the metoprolol cation in MT-o. 
Figure 3. Superimposition of the X-ray structures of the cationic species found in the CSD plus 
in MT-o.  Structures are superimposed by “ball-and-stick” atoms. Hydrogen atoms have been 
omitted for clarity. Color key: MS-m = green; MT-o = red; JIRWIR = pale blue; CIMJUD = 
purple; QAJYIL = orange; DETHIU = brown. 
Figure 4. Superimposition of the X-ray structures of the neutral species found in the CSD.  
Structures are superimposed by “ball-and-stick” atoms.  Hydrogen atoms have been omitted for 
clarity. Color key: BEMBOK = pale green; CEZVIN = dark blue; CIDHAZ = green/fuchsia; 
GAPZEE = brown; KAZPOQ = turquoise; ROKNUB = black.  
Figure 5. Superimposition of the X-ray structures of the cationic and neutral species. Structures 
are superimposed by “ball-and-stick” atoms.  Hydrogen atoms have been omitted for clarity. For 
color key definition see figures 3 and 4. 
Figure 6. Superimposition of the X-ray structures of the S enantiomer found in MS-m (green) 
and MT-o (red). Structures are superimposed by “ball-and-stick” atoms. Hydrogen atoms have 
been omitted for clarity 
Figure 7. A) base-unit of  ribbons in MT-o viewed along the c axis; B) chains of alternating R 
and S metoprolol cations paired by tartrate anions in MT-o viewed along the b axis. 
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Figure 8. Crystal packing of MT-o (view along the b axis). 
Figure 9. Metoprolol succinate ribbons as present in the crystal packing of MS-m.  
Figure 10. Superimposition of the XRPD patterns of MT-o collected at 173, 183, 213, 243, 273 
K in vacuum (A) and  303, 323, 348, 373 K in air (B). In (B) for comparative purposes the 
XRPD patterns collected at 243  and 273 K in vacuum are also reported. 
Figure 11. Superimposition of XRPD patterns of MT-o collected after the melting and then after 
four (top), six and fourteen days (bottom). 
Figure 12. Superimposition of the XRPD patterns of compound MS-m at different temperatures 
(303, 323, 348 and 373 K).  
 
SCHEMES  
Scheme 1. Schematic drawing of the metoprolol molecule. 






Table 1. Crystallographic data and refinement parameters for MT-o. 
Empirical formula C34H56N2O12 
Formula weight 684.80 
T (K) 100 
Crystal system, space group orthorhombic, P21221 
 (Å) 1.54184 
Unit cell dimensions (Å) a = 45.51(1)   
b = 8.484(2)  
c = 9.489(1)    
Volume (Å3)  3664(1) 
Z, dcalc(g/cm
3) 4, 1.242   
(mm-1) 0.774 
Refinement method Full-matrix least-squares on F2 
Reflections collected / unique 10032/3906 (Rint =0.0690) 
Data / parameters / restrains 3906/428/6 
Final R indices [I>2(I)] R1 = 0.0671, wR2 = 0.1569 
R indices (all data) R1 = 0.1360, wR2 = 0.1967 
 
Table 2. Main torsion angles (°), obtained from X-ray diffraction studies, defining the overall 
shape of the S enantiomer of metoprolol cations in MS-m, MT-o and MT-m. 
Dihedral Angles (°) MS-m1 MT-o   MT-m 2 
C(2)-C(1)-O(1)-C(7) 1.48(1)3 10(3) 10/9 
C(1)-O(1)-C(7)-C(8) -177.6(1) 167(1) 166/169 
O(1)-C(7)-C(8)-C(9) -65.1(2) -174(1) -171/-169 
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C(7)-C(8)-C(9)-N(1) 166.9(1) 156(1) 161/158 
C(8)-C(9)-N(1)-C(10) 172.0(1) 176(1) 177/176 
C(9)-N(1)-C(10)-C(11) 177.5(1) 166(1) 165/171 
C(15)-O(3)-C(14)-C(13) -170.6(2) -174(1) -177/-175 
O(3)-C(14)-C(13)-C(4) 175.1(1) -173.(1) -177/-175 
C(14)-C(13)-C(4)-C(3) 52.5(2) -96(2) -91/-89 
1From ref. 26, angular values refer to the S cation found in the crystal lattice. 
2From ref. 14, angular values refer to the two independent S cations found in the crystal lattice.  
3Value refers to the C(6)-C(1)-O(1)-C(7) in the Di Vaira paper.26 
 
Table 3. Selected intermolecular interactions in MS-m26 and  MT-o.  
Strong H-bonds  
MS-m MT-o 
 X...Y  (Å) - H...Y (Å) – X-
H...Y (°) 
 X...Y  (Å) - H...Y (Å) – X-
H...Y (°) 
N-H(1N)···O(5)1 2.745(2) – 1.85 – 162  N(1a)-H(1a2)...O(5a) 2.73(2) – 1.92 – 150  
N(1b)-H(1b2)...O(5b) 2.78(2) – 1.93 – 160 
 N-H(2N)···O(4)2 2.796(2) – 1.89 – 170  N(1a)-H(1a1)...O(4b)3 2.70(2) – 1.85 – 157 
N(1b)-H(1b1)...O(4a) 2.85(2) – 1.99 – 165  
O(2)-
H(2O)···O(4)1 
2.723(2) – 1.88 – 179  O(2a)-H(2a)...O(4a) 2.58(2) – 2.00 – 128  
O(2b)-H(2b)...O(4b) 2.68(1) – 2.19 – 119  
1 x, -y, z-1/2; 2 –x+1, y, -z+3/2; 3 x, y, z-1 
 
Weak interactions 
C-H...π interactions in Ms-m (data from ref.26)  
 H…CT4 (Å) C-H…CT (°) H-CT/(C1-C6)mean plane (°) 
C(13)-H(132)...CT5 2.79 160 82 
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C(14)-H(142) ...CT6 2.84 157 81 
Weak H-bonds in MT-o  
X-H...Y X...Y  (Å) H...Y (Å) X-H...Y (°) 
C(11a)-H(11c)...O(5b)7 3.32(3) 2.40 160 
C(13a)-H(13b)-O(3b)8 3.70(2) 2.83 149 
C(3a)-H(3a)-O(3b)8 3.44(2) 2.59 152 
C(12b)-H(12e)...O(5a)9 3.65(2) 2.77 155 
C(3b)-H(3b)-O(3a)10 3.44(2) 2.58 153 
C(13b)-H(13d)-O(3a)10 3.56(2) 2.66 154 
4CT is the centroid of the C1-C6 aromatic ring;
 5 = -x+1/2,+y-1/2,-z+3/2; 6 = -x+1/2,+y+1/2,-z+3/2; 7 x, 
y-1, z-1; 8-x+3/2, -y, z-1/2 
 ; 9 x, y+1, z; 10 -x+3/2, -y+1, z+1/2. 
 
 
Table 4. Cell parameter for MS-m at different temperature from XRPD data. 
 a(Å) b(Å) c(Å) β(°) V(Å3) Rwp 
200K 26.30(2) 7.980(6) 17.54(2) 107.31(5) 3514.4(1) 8.61 
273K 26.33(2) 8.077(6) 17.51(2) 107.31(5) 3555.2(1) 8.43 
298K 26.34(2) 8.121(5) 17.50(2) 107.27(6) 3574.6(1) 8.81 
323K 26.36(2) 8.160(4) 17.48(2) 107.27(6) 3590.4(1) 8.73 
348K 26.36(2) 8.200(3) 17.46(2) 107.35(7) 3602.3(1) 8.63 
373K 26.41(2) 8.259(3) 17.46(2) 107.32(6) 3635.7(1) 8.62 
393K 26.45(2) 8.300(4) 17.46(2) 107.40(8) 3657.7(1) 8.64 
 
Table 5. Linear (α) and volume (β) thermal expansion coefficients (TECs)63 calculated for MS-
m taking as reference the cell parameter values calculated at 200K. 
T(K) αa(10-5) C-1 αb(10-5) C-1 αc(10-5) C-1 β(10-4) C-1 
 24 
200     
273 1.6 16.7 -2.3  1.6 
298 1.6 18.0 -2.3 1.8 
323 1.9 18.3 -2.8 1.8 
348 1.5 18.6 -3.1 1.7 
373 2.4 20.2 -2.6 2.0 
393 3.0 20.8 -2.4 2.1 
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